|5.51||-0.6200||-10.11%||Vol 16.19M||1Y Perf -43.71%|
|Dec 6th, 2023 16:00 DELAYED|
|- -||-0.05 -0.91%|
|Target Price||16.89||Analyst Rating||Strong Buy 1.50|
|Potential %||206.53||Finscreener Ranking||★★★★+ 56.33|
|Insiders Trans % 3/6/12 mo.||-/-100/-75||Value Ranking||★★+ 47.83|
|Insiders Value % 3/6/12 mo.||-/-100/-89||Growth Ranking||★★★★ 59.52|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-87||Income Ranking||— -|
|Price Range Ratio 52W %||8.65||Earnings Rating||Sell|
|Market Cap||1.13B||Earnings Date||2nd Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.25|
|EPS Growth Next 5 Years %||30.00|
|Avg. Weekly Volume||3.17M|
|Avg. Monthly Volume||2.74M|
|Avg. Quarterly Volume||2.57M|
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) stock closed at 6.13 per share at the end of the most recent trading day (a -0.97% change compared to the prior day closing price) with a volume of 3.22M shares and market capitalization of 1.13B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 140 people. BioCryst Pharmaceuticals Inc. CEO is Jon P. Stonehouse.
The one-year performance of BioCryst Pharmaceuticals Inc. stock is -43.71%, while year-to-date (YTD) performance is -46.6%. BCRX stock has a five-year performance of -31.51%. Its 52-week range is between 4.825 and 12.745, which gives BCRX stock a 52-week price range ratio of 8.65%
BioCryst Pharmaceuticals Inc. currently has a PE ratio of -11.30, a price-to-book (PB) ratio of 56.59, a price-to-sale (PS) ratio of 10.36, a price to cashflow ratio of -, a PEG ratio of -0.38, a ROA of -49.34%, a ROC of -96.99% and a ROE of 105.31%. The company’s profit margin is -91.79%, its EBITDA margin is -40.20%, and its revenue ttm is $191.28 Million , which makes it $1.03 revenue per share.
Of the last four earnings reports from BioCryst Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.25 for the next earnings report. BioCryst Pharmaceuticals Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for BioCryst Pharmaceuticals Inc. is Strong Buy (1.5), with a target price of $16.89, which is +206.53% compared to the current price. The earnings rating for BioCryst Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BioCryst Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BioCryst Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 23.81, ATR14 : 0.35, CCI20 : 135.56, Chaikin Money Flow : 0.03, MACD : 0.04, Money Flow Index : 64.34, ROC : 19.26, RSI : 59.73, STOCH (14,3) : 83.22, STOCH RSI : 0.91, UO : 60.15, Williams %R : -16.78), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BioCryst Pharmaceuticals Inc. in the last 12-months were: Alane Barnes (Sold 4 175 shares of value $45 424 ), Anthony Doyle (Sold 5 700 shares of value $62 130 ), Charles K. Gayer (Sold 6 100 shares of value $66 490 ), Helen M. Thackray (Sold 17 125 shares of value $150 091 ), Jon P. Stonehouse (Option Excercise at a value of $644 997), Jon P. Stonehouse (Sold 114 100 shares of value $1 191 690 ), Kenneth B. Lee (Option Excercise at a value of $25 650), Michael L. Jones (Sold 445 shares of value $4 851 ), Nancy J. Hutson (Sold 12 866 shares of value $103 443 ), Stonehouse Jon (Option Excercise at a value of $644 997), Stonehouse Jon (Sold 100 000 shares of value $1 038 000 )
Mon, 18 Sep 2023 10:45 GMT BioCryst (BCRX) was upgraded to a Buy Rating at RBC Capital- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.